Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
Núria Chic, Francesco Schettini, Fara Brasó‐Maristany, et al.
EBioMedicine (2021) Vol. 69, pp. 103451-103451
Open Access | Times Cited: 11

Showing 11 citing articles:

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Cancer (2024) Vol. 130, Iss. 16, pp. 2746-2762
Open Access | Times Cited: 9
Phytoestrogens: Chemistry, potential health benefits, and their medicinal importance
Vivek P. Chavda, Amit Z. Chaudhari, Pankti C. Balar, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 6, pp. 3060-3079
Open Access | Times Cited: 8
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications
Gaia Griguolo, Michele Bottosso, Grazia Maria Vernaci, et al.
Cancer Treatment Reviews (2021) Vol. 102, pp. 102323-102323
Open Access | Times Cited: 29
Hormone receptor-positive early breast cancer in young women: A comprehensive review
Benjamín Walbaum, Isabel García-Fructuoso, Olga Martínez‐Sáez, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102804-102804
Closed Access | Times Cited: 4
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 3-4, pp. 117-135
Closed Access | Times Cited: 2
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
Mengping Long, Chong You, Qianqian Song, et al.
Life (2022) Vol. 13, Iss. 1, pp. 74-74
Open Access | Times Cited: 9
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer
Carlos Martínez-Pérez, Arran Turnbull, Charlene Kay, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 1, pp. 67-86
Open Access | Times Cited: 5
Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α–Positive Mammary Adenocarcinomas
Priscilla A. Furth, Weisheng Wang, Keunsoo Kang, et al.
American Journal Of Pathology (2022) Vol. 193, Iss. 1, pp. 103-120
Open Access | Times Cited: 7
Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso
Abdou Azaque Zouré, Lanyo Jospin Amegnona, Nayi Zongo, et al.
Open Life Sciences (2021) Vol. 16, Iss. 1, pp. 1101-1110
Open Access | Times Cited: 9
Risk prediction models for chemotherapy-related nausea and vomiting in patients with cancer: A systematic review and meta-analysis
Mengna Luo, Shaoping Nie, Qiulan Yang, et al.
Research Square (Research Square) (2024)
Open Access
Ovarian function suppression as a potential mechanism of chemotherapy
Juan Luis Gomez Marti, Azadeh Nasrazadani, Adam Brufsky
EBioMedicine (2021) Vol. 70, pp. 103489-103489
Open Access | Times Cited: 1
Page 1

Scroll to top